



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	N/A (not a randomized trial) (Title on p1)
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	p3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	p4-5
	2b	Specific objectives or hypotheses	p5
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	p14
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	All amendments detailed in the supplied study protocol (available in Supplementary Information)
Participants	4a	Eligibility criteria for participants	p15, and in the supplied study protocol (available in Supplementary Information)
	4b	Settings and locations where the data were collected	p14
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	p15-17

Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	p17-18
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	p18/19
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	N/A
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	N/A
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	N/A
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	N/A
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	N/A (open label trial)
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	p18-19 (1 arm only), and in the supplied statistical analysis plan (available in Supplementary Information)
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	p18-19, and in the supplied statistical analysis plan (available in Supplementary Information)

## Results

Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	p5 and Extended Data Fig. 1
	13b	For each group, losses and exclusions after randomisation, together with reasons	p5 and Extended Data Fig. 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	p5
	14b	Why the trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	p24-26 (Table 1)
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	p5-9 and Extended Data Fig. 1
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	p6-7 and p 27 (Table 2) (statistical testing not done for safety)
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	p7-8, p18, Fig 2-4, and Extended Data Fig 2.
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	P8-10, p28-29 (Table 3), Extended Data Fig. 3, and Extended Data Tables 3-5)
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	p10-14

Generalisability	21	Generalisability (external validity, applicability) of the trial findings	p10-11
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	p10-14
<b>Other information</b>			p3, p5 and p14
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	p17 (redacted protocol provided in the Supplementary Information)
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	p21 (Regeneron Pharmaceuticals, Inc.)

Citation: Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine. 2010;8:18. © 2010 Schulz et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).